Focused On-demand Library for ADP-ribosylation factor-like protein 13B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q3SXY8

UPID:

AR13B_HUMAN

Alternative names:

ADP-ribosylation factor-like protein 2-like 1

Alternative UPACC:

Q3SXY8; D3DN29; G3V1S8; Q504W8; Q8TCL5

Background:

ADP-ribosylation factor-like protein 13B, also known as ARL13B, plays a pivotal role in the structure and function of cilia, essential for cellular signaling and development. It is involved in maintaining the ciliary axoneme structure, crucial for neural tube patterning and cerebral cortex development. ARL13B's interaction with GTP, despite its unclear GTPase activity, underscores its significance in cellular processes.

Therapeutic significance:

ARL13B's mutation is linked to Joubert syndrome 8, characterized by cerebellar ataxia and a range of developmental issues. Understanding the role of ARL13B could open doors to potential therapeutic strategies for treating this complex disorder.